1
|
Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv 2024:2024.01.14.575609. [PMID: 38293222 PMCID: PMC10827101 DOI: 10.1101/2024.01.14.575609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half of patients achieve complete renal response with standard immunosuppressants. Identifying non-invasive, blood-based pathologic immune alterations associated with renal injury could aid therapeutic decisions. Here, we used mass cytometry immunophenotyping of peripheral blood mononuclear cells in 145 patients with biopsy-proven LN and 40 healthy controls to evaluate the heterogeneity of immune activation in patients with LN and to identify correlates of renal parameters and treatment response. Unbiased analysis identified 3 immunologically distinct groups of patients with LN that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at one year. Patients with enriched circulating granzyme B+ T cells at baseline showed more severe disease and increased numbers of activated CD8 T cells in the kidney, yet they had the highest likelihood of treatment response. A second group characterized primarily by a high type I interferon signature had a lower likelihood of response to therapy, while a third group appeared immunologically inactive by immunophenotyping at enrollment but with chronic renal injuries. Main immune profiles could be distilled down to 5 simple cytometric parameters that recapitulate several of the associations, highlighting the potential for blood immune profiling to translate to clinically useful non-invasive metrics to assess immune-mediated disease in LN.
Collapse
|
2
|
Wolff L, Horisberger A, Moi L, Karampetsou MP, Comte D. Polyarteritis Nodosa: Old Disease, New Etiologies. Int J Mol Sci 2023; 24:16668. [PMID: 38068989 PMCID: PMC10706353 DOI: 10.3390/ijms242316668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 11/11/2023] [Accepted: 11/17/2023] [Indexed: 12/18/2023] Open
Abstract
Polyarteritis nodosa (PAN), also known as panarteritis nodosa, represents a form of necrotizing vasculitis that predominantly affects medium-sized vessels, although it is not restricted to them and can also involve smaller vessels. The clinical presentation is heterogeneous and characterized by a significant number of patients exhibiting general symptoms, including asthenia, fever, and unintended weight loss. Although PAN can involve virtually any organ, it preferentially affects the skin, nervous system, and the gastrointestinal tract. Orchitis is a rare but specific manifestation of PAN. The absence of granulomas, glomerulonephritis, and anti-neutrophil cytoplasmic antibodies serves to distinguish PAN from other types of vasculitis. Major complications consist of hemorrhagic and thrombotic events occurring in mesenteric, cardiac, cerebral, and renal systems. Historically, PAN was frequently linked to hepatitis B virus (HBV) infection, but this association has dramatically changed in recent years due to declining HBV prevalence. Current epidemiological research often identifies a connection between PAN and genetic syndromes as well as neoplasia. This article provides a comprehensive review of PAN, specifically focusing on the progression of its clinical manifestations over time.
Collapse
Affiliation(s)
- Louis Wolff
- Department of Internal Medicine, Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium;
| | - Alice Horisberger
- Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA;
- Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland
| | - Laura Moi
- Immunology and Allergology, Institut Central des Hôpitaux, Valais Hospital, 1951 Sion, Switzerland;
| | | | - Denis Comte
- Department of Medicine, Division of Internal Medicine, Lausanne University Hospital, University of Lausanne, 1005 Lausanne, Switzerland
| |
Collapse
|
3
|
Inamo J, Keegan J, Griffith A, Ghosh T, Horisberger A, Howard K, Pulford J, Murzin E, Hancock B, Jonsson AH, Seifert J, Feser ML, Norris JM, Cao Y, Apruzzese W, Louis Bridges S, Bykerk V, Goodman S, Donlin L, Firestein GS, Perlman H, Bathon JM, Hughes LB, Tabechian D, Filer A, Pitzalis C, Anolik JH, Moreland L, Guthridge JM, James JA, Brenner MB, Raychaudhuri S, Sparks JA, Michael Holers V, Deane KD, Lederer JA, Rao DA, Zhang F. Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis. bioRxiv 2023:2023.07.03.547507. [PMID: 37461737 PMCID: PMC10349983 DOI: 10.1101/2023.07.03.547507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in 'At-Risk' populations prior to clinical disease onset is crucial to establishing effective prevention strategies. Here, we applied mass cytometry to deeply characterize the immunophenotypes in blood from At-Risk individuals identified through the presence of serum antibodies to citrullinated protein antigens (ACPA) and/or first-degree relative (FDR) status (n=52), as compared to established RA (n=67), and healthy controls (n=48). We identified significant cell expansions in At-Risk individuals compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 low naïve B cell population was expanded in ACPA-positive FDRs. Further, we developed an "RA immunophenotype score" classification method based on the degree of enrichment of cell states relevant to established RA patients. This score significantly distinguished At-Risk individuals from controls. In all, we systematically identified activated lymphocyte phenotypes in At-Risk individuals, along with immunophenotypic differences among both ACPA+ and ACPA-FDR At-Risk subpopulations. Our classification model provides a promising approach for understanding RA pathogenesis with the goal to further improve prevention strategies and identify novel therapeutic targets.
Collapse
|
4
|
Horisberger A, Humbel M, Fluder N, Bellanger F, Fenwick C, Ribi C, Comte D. Measurement of circulating CD21 -CD27 - B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers. Sci Rep 2022; 12:9189. [PMID: 35654865 PMCID: PMC9163192 DOI: 10.1038/s41598-022-12775-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 05/16/2022] [Indexed: 12/17/2022] Open
Abstract
Determining disease activity in systemic lupus erythematosus (SLE) patients is challenging and limited by the lack of reliable biomarkers. Abnormally activated B cells play a key role in the pathogenesis of SLE, but their measure in clinical practice is currently not recommended. Here, we studied peripheral B cells to identify a valid biomarker. We analyzed peripheral B cells in a discovery cohort of 30 SLE patients compared to 30 healthy controls (HC) using mass cytometry and unsupervised clustering analysis. The relevant B cell populations were subsequently studied by flow cytometry in a validation cohort of 63 SLE patients, 28 autoimmune diseases controls and 39 HC. Our data show an increased frequency of B cell populations with activated phenotype in SLE compared to healthy and autoimmune diseases controls. These cells uniformly lacked the expression of CD21 and CD27. Measurement of CD21−CD27− B cells in the blood identified patients with active disease and their frequency correlated with disease severity. Interestingly, we did not observe an increase in the frequency of CD21−CD27− B cells in patients with clinically inactive disease but with elevated conventional biomarkers (anti-dsDNA and complement levels). Accordingly, measurement of CD21−CD27− B cells represents a robust and easily accessible biomarker to assess the activity of the disease in SLE patients.
Collapse
Affiliation(s)
- Alice Horisberger
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Morgane Humbel
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Natalia Fluder
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Florence Bellanger
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Craig Fenwick
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Camillo Ribi
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland
| | - Denis Comte
- Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, 46, Rue du Bugnon, 1011, Lausanne, Switzerland.
| |
Collapse
|
5
|
Fluder N, Humbel M, Bellanger F, Horisberger A, Fenwick C, Ribi C, Comte D. POS0099 THE CELLULAR METABOLISM OF SLE NK CELLS IS PRIMARILY ALTERED AT THE LEVEL OF MITOCHONDRIAL RESPIRATION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSystemic lupus erythematosus (SLE) is an inflammatory autoimmune disease, involving the development of autoreactive cells and autoantibodies. Natural Killer (NK) cells are innate immune cells that mediate the interaction between the innate and adaptive immune system, however their role in SLE is incompletely understood. SLE NK cells are decreased in peripheral blood, exhibit reduced cytotoxicity, and impaired cytokine production (1, 2). Furthermore, SLE NK cells present phenotypic alterations: increased expression of CD38 and altered upregulation of SLAMF7 after activation (3). To date, few studies evaluated the molecular mechanisms underlying NK cell dysfunction in SLE.ObjectivesWe examined immunometabolic alterations of SLE NK cells. First, we characterized the cellular metabolism of SLE NK cells by assessing glycolysis and oxidative phosphorylation (OXPHOS) at basal level. Then, we evaluated how cellular metabolism can be manipulated to enhance NK cell function. In this perspective, we examined how the ligation of CD38 with daratumumab (DARA) and SLAMF7 with elotuzumab (ELO) modulate glycolysis and OXPHOS.MethodsNK cells of cryopreserved PBMC from SLE patients were isolated. Glycolysis and OXPHOS were studied using XFe96 Seahorse. Expression of metabolic receptors (CD71, GLUT-1, CD98), mitochondrial function (mitochondrial membrane potential, mass) and calcium influx were investigated by FACS. Mitochondrial structure was evaluated by electron and confocal microscopy.ResultsFirst, we examined the cellular metabolism of SLE NK cells compared to healthy cells. We observed that OXPHOS is significantly increased in SLE NK cells (Figure 1A), whereas glycolysis was normal (Figure 1B). Furthermore, the mitochondrial mass and membrane potential (by FACS (Figure 1C) and confocal microscopy) were increased in SLE. Electron microscope imaging showed profound alterations in SLE NK cell mitochondrial ultrastructure (Figure 1D). No significant differences in the expression of key metabolite transporters involved in mitochondrial fueling (CD71, GLUT-1, CD98) was observed in SLE NK cells compared to healthy controls.Second, we examined how ligation of DARA and ELO influences the metabolism of healthy NK cells. Our data showed that ELO primarily enhances NK cell OXPHOS (Figure 1E), whereas DARA mainly increases glycolysis. Consistently, ELO also increases mitochondrial membrane potential and expression of metabolite transporters CD71, GLUT-1 and CD98. Next, we examined the effect of DARA and ELO on SLE NK cells. While stimulation with DARA adequately increases glycolysis in SLE NK cells, engagement with ELO fails to properly increase OXPHOS (Figure 1F), expression of cell surface transporters, mitochondrial membrane potential and mass.ConclusionOur data suggest that SLE NK cells exhibit alterations in cellular metabolism, primarily involving mitochondrial respiration. In contrast, glucose metabolism is similar to that of healthy NK cells. Additionally, ELO and DARA mediate the activation of healthy NK cells through the engagement of different metabolic pathways: OXPHOS and glycolysis, respectively. Therefore, priming SLE NK cells with ELO is unable to adequately engage their dysfunctional mitochondrial respiration. These findings provide important insights on the alteration present in SLE NK cells and contribute to a better understanding of the pathogenesis of the disease.References[1]Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. J Leukoc Biol. 2015;98(4):479-87.[2]Park Y-W, Kee S-J, Cho Y-N, Lee E-H, Lee H-Y, Kim E-M, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis & Rheumatism. 2009;60(6):1753-63.[3]Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, et al. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. Front Immunol. 2021;12:645478.AcknowledgementsThis study received funding from the Swiss National Science Foundation (Ambizione PZ00P3_173950 to DC).Disclosure of InterestsNone declared
Collapse
|
6
|
Humbel M, Bellanger F, Horisberger A, Suffiotti M, Fluder N, Makhmutova M, Mathias A, Du Pasquier R, Fenwick C, Ribi C, Comte D. SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus. Front Immunol 2022; 13:843059. [PMID: 35603218 PMCID: PMC9120573 DOI: 10.3389/fimmu.2022.843059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 04/11/2022] [Indexed: 11/25/2022] Open
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, linked to alterations in both the innate and the adaptive immune system. Due to the heterogeneity of the clinical presentation, the diagnosis of SLE remains complicated and is often made years after the first symptoms manifest, delaying treatment, and worsening the prognosis. Several studies have shown that signaling lymphocytic activation molecule family (SLAMF) receptors are aberrantly expressed and dysfunctional in SLE immune cells, contributing to the altered cellular function observed in these patients. The aim of this study was to determine whether altered co-/expression of SLAMF receptors on peripheral blood mononuclear cells (PBMC) identifies SLE characteristic cell populations. To this end, single cell mass cytometry and bioinformatic analysis were exploited to compare SLE patients to healthy and autoimmune diseases controls. First, the expression of each SLAMF receptor on all PBMC populations was investigated. We observed that SLAMF1+ B cells (referred to as SLEB1) were increased in SLE compared to controls. Furthermore, the frequency of SLAMF4+ monocytes and SLAMF4+ NK were inversely correlated with disease activity, whereas the frequency SLAMF1+ CD4+ TDEM cells were directly correlated with disease activity. Consensus clustering analysis identified two cell clusters that presented significantly increased frequency in SLE compared to controls: switch memory B cells expressing SLAMF1, SLAMF3, SLAMF5, SLAMF6 (referred to as SLESMB) and circulating T follicular helper cells expressing the same SLAMF receptors (referred to as SLEcTFH). Finally, the robustness of the identified cell populations as biomarkers for SLE was evaluated through ROC curve analysis. The combined measurement of SLEcTFH and SLEB1 or SLESMB cells identified SLE patients in 90% of cases. In conclusion, this study identified an immune signature for SLE based on the expression of SLAMF receptors on PBMC, further highlighting the involvement of SLAMF receptors in the pathogenesis of SLE.
Collapse
Affiliation(s)
- Morgane Humbel
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Florence Bellanger
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Alice Horisberger
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Madeleine Suffiotti
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Natalia Fluder
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Mariko Makhmutova
- Machine Learning and Optimization Laboratory, Swiss Federal Institute of Technology in Lausanne, Lausanne, Switzerland
| | - Amandine Mathias
- Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
| | - Renaud Du Pasquier
- Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland
| | - Craig Fenwick
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Camillo Ribi
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Denis Comte
- Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
7
|
Tsilimidos G, Horisberger A, Ribi C, Cairoli A, Stalder G. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction. Clin Lymphoma Myeloma Leuk 2021; 21:e745-e747. [PMID: 34158264 DOI: 10.1016/j.clml.2021.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Accepted: 05/16/2021] [Indexed: 06/13/2023]
Affiliation(s)
- Gerasimos Tsilimidos
- Division and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne.
| | - Alice Horisberger
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Camillo Ribi
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Anne Cairoli
- Division and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne
| | - Gregoire Stalder
- Division and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne
| |
Collapse
|
8
|
Clottu A, Horisberger A, Comte D. [Biologics and systemic lupus erythematosous : new insights and perspectives]. Rev Med Suisse 2021; 17:684-689. [PMID: 33830700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Systemic lupus erythematosus is a complex autoimmune disease that remains challenging to treat. Recent advances in the understanding of the pathogenesis of SLE pave the way for the evaluation of biologic medicine. The most promising therapeutic targets in SLE are those that interfere with B cells count or normal function, interferon inhibitors, JAK inhibitors and biologicals that alter the cytokines imbalance that characterizes SLE. Recent phase 3 clinical trials have evaluated the role of belimumab in lupus nephritis and the usefulness of anifrolumab in the treatment of moderate to severe SLE. Many more trials are currently underway and may improve the level of care of patients with SLE in the near future.
Collapse
Affiliation(s)
| | | | - Denis Comte
- Service d'immunologie et allergie, CHUV, 1011 Lausanne
| |
Collapse
|
9
|
Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, Ribi C, Comte D. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. Front Immunol 2021; 12:645478. [PMID: 33828555 PMCID: PMC8019934 DOI: 10.3389/fimmu.2021.645478] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 02/26/2021] [Indexed: 11/13/2022] Open
Abstract
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by multiple cellular and molecular dysfunctions of the innate and adaptive immunity. Cytotoxic function of NK cells is compromised in patients with SLE. Herein, we characterized the phenotypic alterations of SLE NK cells in a comprehensive manner to further delineate the mechanisms underlying the cytotoxic dysfunction of SLE NK cells and identify novel potential therapeutic targets. Therefore, we examined PBMC from SLE patients and matched healthy controls by single-cell mass cytometry to assess the phenotype of NK cells. In addition, we evaluated the cell function of NK cells (degranulation and cytokine production) and the killing of B cell subpopulations in a B cell-NK cell in vitro co-culture model. We found that SLE NK cells expressed higher levels of CD38 and were not able to adequately upregulate SLAMF1 and SLAMF7 following activation. In addition, ligation of SLAMF7 with elotuzumab or of CD38 with daratumumab on SLE NK cells enhanced degranulation of both healthy and SLE NK cells and primed them to kill circulating plasma cells in an in vitro co-culture system. Overall, our data indicated that dysregulated expression of CD38, SLAMF1 and SLAMF7 on SLE NK cells is associated with an altered interplay between SLE NK cells and plasma cells, thus suggesting their contribution to the accumulation of (auto)antibody producing cells. Accordingly, targeting SLAMF7 and CD38 may represent novel therapeutic approaches in SLE by enhancing NK cell function and promoting elimination of circulating plasma cell.
Collapse
Affiliation(s)
- Morgane Humbel
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Florence Bellanger
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Natalia Fluder
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Alice Horisberger
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Madeleine Suffiotti
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Craig Fenwick
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Camillo Ribi
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Denis Comte
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
10
|
Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, Kuntzer T, de Leval L, Carballares M, Hurni CA, Rusca M, Pantet O, Di Bernardo S, Oddo M, Comte D, Piquilloud L. Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. Swiss Med Wkly 2020; 150:w20387. [PMID: 33181855 DOI: 10.4414/smw.2020.20387] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A 22-year-old male with a typical history of pauci-symptomatic COVID-19 3 weeks earlier, confirmed by positive serology for SARS-CoV-2 (IgG), was admitted to the intensive care unit because of severe myocarditis with refractory cardiogenic shock that required extracorporeal life support. Due to a clinical presentation suggestive of Kawasaki-like disease with coronary aneurysm and severe systemic inflammation, intravenous immunoglobulins were administered in combination with tocilizumab. The initial clinical course was favourable with these treatments. However, the patient subsequently developed a severe mononeuritis multiplex leading to bilateral foot drop, which required intensive immunosuppressive therapy (corticosteroids, cyclophosphamide and rituximab). The clinical presentation meets the criteria for multisystem inflammatory syndrome associated with SARS-CoV-2, but includes very severe organ damages. Early recognition, a multidisciplinary approach and aggressive therapeutic intervention can lead to a favourable outcome.
Collapse
Affiliation(s)
- Alexandra Othenin-Girard
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland / Anaesthesiology Service, Lausanne University Hospital, Lausanne, Switzerland
| | - Julien Regamey
- Cardiology Service, Lausanne University Hospital, Lausanne, Switzerland
| | - Frédéric Lamoth
- Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland / Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland / University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
| | - Alice Horisberger
- Immunology and Allergy Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | | | - Jean-Benoit Epiney
- Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland
| | - Thierry Kuntzer
- University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland / Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland
| | - Laurence de Leval
- University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland / Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, Lausanne, Switzerland
| | - Maude Carballares
- Emergency Medicine Service, Lausanne University Hospital, Lausanne, Switzerland
| | - Claire-Anne Hurni
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland
| | - Marco Rusca
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland
| | - Olivier Pantet
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland / University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
| | - Stefano Di Bernardo
- University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland / Paediatric Cardiology Service, Department of Woman-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland
| | - Mauro Oddo
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland / University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
| | - Denis Comte
- University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland / Immunology and Allergy Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Lise Piquilloud
- Adult Intensive Care Unit, Lausanne University Hospital, Lausanne, Switzerland / University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
| |
Collapse
|
11
|
Horisberger A, Moi L, Ribi C, Comte D. Impact of COVID-19 pandemic on SLE: beyond the risk of infection. Lupus Sci Med 2020; 7:7/1/e000408. [PMID: 32376774 PMCID: PMC7223264 DOI: 10.1136/lupus-2020-000408] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 04/24/2020] [Indexed: 01/08/2023]
Affiliation(s)
- Alice Horisberger
- Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - Laura Moi
- Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - Camillo Ribi
- Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - Denis Comte
- Service of Immunology and Allergy, Departement de medecine, Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| |
Collapse
|
12
|
Horisberger A, Moi L, Ribi C, Comte D. [Autoimmune diseases in the context of pandemic COVID-19]. Rev Med Suisse 2020; 16:827-830. [PMID: 32348045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak.
Collapse
Affiliation(s)
- Alice Horisberger
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Laura Moi
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Camillo Ribi
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Denis Comte
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| |
Collapse
|
13
|
Doms J, Horisberger A, Ribi C. [Management of the antiphospholipid syndrome in adults]. Rev Med Suisse 2020; 16:670-674. [PMID: 32270932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The antiphospholipid syndrome (APS) is a complex autoimmune -disease characterized by the expression of antiphospholipid -antibodies (APL) and a variety of clinical presentation. The latest classification defines APS by the occurrence of vascular thrombosis and/or typical obstetrical morbidity together with persistently -detectable APL at least 12 weeks apart. The latest recommendation proposes a risk profile based on the type and titer of APL detected, in order to guide the intensity of prophylactic measures. Based on current knowledge, novel oral anticoagulants should not be used in APS, particularly in patients with a high-risk APL profile or arterial thrombosis. Beyond the mere aspect of anticoagulant treatment, immunomodulatory approaches to the APS such as hydroxychloroquine are under investigation.
Collapse
Affiliation(s)
- Jacqueline Doms
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Alice Horisberger
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Camillo Ribi
- Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne
| |
Collapse
|
14
|
Horisberger A, Pantazou V, Cuendet G, Ribi C, Dunet V, Théaudin M. ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis. Mult Scler 2020; 26:1599-1602. [DOI: 10.1177/1352458519895449] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Alemtuzumab is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. In contrast to rare cases of immune-mediated cutaneous vasculitis, systemic vasculitis after alemtuzumab has not yet been described. We report the case of a 29-year-old man with RRMS who developed fever, auricular chondritis, cutaneous vasculitis and life-threatening diffuse alveolar haemorrhage, 12 months after alemtuzumab. Antibodies to myeloperoxidase appeared 9 months after alemtuzumab and were extremely high at the time of vasculitis. Outcome was favourable after glucocorticoids, plasma exchanges and rituximab. Thus, alemtuzumab may induce life-threatening vasculitis in patients treated for RRMS.
Collapse
Affiliation(s)
- Alice Horisberger
- Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Vasiliki Pantazou
- Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Géraldine Cuendet
- University General Medicine and Public Health Centre, University of Lausanne, Lausanne, Switzerland
| | - Camillo Ribi
- Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Vincent Dunet
- Department of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| | - Marie Théaudin
- Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
15
|
Horisberger A, Ghosn J, Di Lucca J, Comte D. [From isolated cutaneous vasculitis to systemic disease : a diagnostic approach to purpura in the adult patient]. Rev Med Suisse 2019; 15:713-718. [PMID: 30942968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Purpura can be a clinical manifestation of various diseases. The causes of purpura are divided into two main categories: thrombocytopenia and vasculopathies. Cutaneous vasculitis belongs to the latter group. Cutaneous vasculitis should be considered a symptom rather than a medical entity. Some forms of cutaneous vasculitis are limited to the skin and are known as isolated cutaneous vasculitis, while other forms may be part of a systemic disease with a more serious prognosis. It is essential to clarify the type and severity of the disease for optimal patient care. A delay in the identification and start of treatment can be the cause of serious and potentially irreversible complications. Through this article, we will propose a step-by-step approach from diagnosis to patient care.
Collapse
Affiliation(s)
- Alice Horisberger
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Jacqueline Ghosn
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1011 Lausanne
| | - Julie Di Lucca
- Service de dermatologie et vénéréologie, CHUV, 1011 Lausanne
| | - Denis Comte
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1011 Lausanne
| |
Collapse
|
16
|
Horisberger A, Courvoisier D, Ribi C. The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study. Arthritis Res Ther 2019; 21:80. [PMID: 30909957 PMCID: PMC6434822 DOI: 10.1186/s13075-019-1864-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 03/11/2019] [Indexed: 12/25/2022] Open
Abstract
Background The vast majority of patients with systemic lupus erythematosus (SLE) complain about fatigue. They also report fatigue as one of their most debilitating symptoms. Yet, in clinical practice, fatigue is only rarely assessed and remains poorly understood. The purpose of this study is to validate the Fatigue Assessment Scale (FAS) and assess the impact of disease activity on fatigue in SLE. Methods A cross-sectional single-center study of patients was included in the Swiss SLE Cohort Study. The FAS and the Short Form 36 (SF-36) were administered to SLE patients and controls with primary Sjogren’s syndrome (pSS) and healthy volunteers (HV) attending our clinic. Disease activity in SLE was captured at the same time as patient-reported outcomes using the SLE Disease Activity Index score with the Safety of Estrogens in SLE National Assessment modification (SELENA-SLEDAI) and the physician’s global assessment. We explored the internal consistency, reproducibility, construct validity, and convergence of the FAS, in comparison to the vitality subscale (VT) of the SF-36. We examined the association of FAS with demographics, disease type, SLE disease activity, and clinical features. Results Of the 73 SLE subjects, 89% were women and 77% were Caucasians. The median age was 43 years, and 23 (32%) patients had active SLE. Demographics in pSS and HV were similar. Within the SLE group, FAS displayed good internal consistency (Cronbach’s alpha = 0.93), unidimensionality, and test-retest reliability (ICC = 0.90). FAS and VT correlated well. The total FAS was highest in active SLE and pSS and higher in non-active SLE compared to HV. Conclusion The FAS is a promising tool to measure fatigue in SLE. Patients with SLE display a significantly higher level of fatigue than HV, which is even more pronounced in active disease and comparable to fatigue levels measured in pSS.
Collapse
Affiliation(s)
- Alice Horisberger
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, CHUV BH09-627, CH-1011, Lausanne, Switzerland.
| | - Delphine Courvoisier
- Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva, Geneva, Switzerland
| | - Camillo Ribi
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, CHUV BH09-627, CH-1011, Lausanne, Switzerland
| |
Collapse
|
17
|
Horisberger A, Mahdi Aljedani R, Spertini F, Ribi C. [Risk of treatment failure and therapeutic novelties in asthma]. Rev Med Suisse 2019; 15:23-26. [PMID: 30629362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Asthma is a chronic disease that is still frequently poorly controlled, despite recent advances in understanding its pathophysiology. Poor compliance and ineffective inhalation technique remain the main causes of treatment failure. The comorbidities associated with asthma, such as obesity and chronic rhinosinusitis, are other elements to consider in the management of patients. Biological treatments targeting inflammation mediators show encouraging results in recurrent asthma exacerbations despite optimal management. However, their benefit remains limited to certain patients, thus requiring the study of predictive biomarkers to better delineate their indication.
Collapse
Affiliation(s)
- Alice Horisberger
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1001 Lausanne
| | - Rima Mahdi Aljedani
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1001 Lausanne
| | - François Spertini
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1001 Lausanne
| | - Camillo Ribi
- Service d'immunologie et allergie, Département de médecine interne, CHUV, 1001 Lausanne
| |
Collapse
|
18
|
Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018; 6:156. [PMID: 30587227 PMCID: PMC6307169 DOI: 10.1186/s40425-018-0481-0] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 12/13/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The prevalence of esophageal stenosis caused by immune checkpoint inhibitors in the context of induced immune mucositis and esophagitis is extremely rare. CASE PRESENTATION We report the case of a patient with stage IV pulmonary adenocarcinoma treated for 6 months with nivolumab who developed bilateral sterile conjunctivitis followed by oropharyngeal mucositis and esophagitis complicated by a severe esophageal stenosis. The laryngeal margin and hypopharyngeal mucosa appeared highly inflammatory with fibrinous deposits. Esophagogastroduodenoscopy revealed mucositis with a scar-like structure immediately below the upper esophageal sphincter with nonulcerative mucosa and an inflammatory aspect of the entire esophagus. No involvement of the stomach was observed. Oropharynx biopsies displayed marked lymphocytic T cell-infiltration with several foci of monocellular necrosis in the squamous epithelium. No morphologic evidence of adenocarcinoma and no signs of mycotic, bacterial or viral infection were noted. A blood sample revealed a discrete increase in the erythrocyte sedimentation rate (ESR) with no eosinophilia or leukocytosis. Liver and kidney function panel tests were normal. A thoracoabdominal CT scan reported no evidence of disease recurrence. Despite multiple boluses of methylprednisolone and high doses of prednisone continued for several months, the patient experienced very rapid symptomatological reappearance during three steroid tapering attempts and aggravation of his esophageal stenosis to an aphagic stage, requiring a nasogastric tube. This long course of high-dose corticosteroid treatment was complicated with osteoporosis-induced fractures with several spontaneous compressions of thoracolumbar vertebrae requiring an enlarged T10 to L5 cementoplasty. Anti-IL-6 blockade therapy with tocilizumab resulted in excellent clinical response, allowing the total resolution of the immune-related adverse events (irAEs) and leading to successful steroid tapering. CONCLUSIONS Herein, we describe the first case of a patient who developed autoimmune mucositis and esophagitis complicated by a severe refractory esophageal stenosis induced during treatment by nivolumab, which completely resolved after personalized treatment with tocilizumab, suggesting a role of IL-6 blockade in the management of severe steroid refractory esophageal stenosis and more broadly in refractory immune-related adverse events.
Collapse
Affiliation(s)
- Alice Horisberger
- Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Stefano La Rosa
- Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital CHUV, rue du Bugnon 25, CH-1011, Lausanne, Switzerland
| | - Jean-Philippe Zurcher
- Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Stefan Zimmermann
- Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - Francois Spertini
- Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland
| | - George Coukos
- Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland
- Ludwig Institute for Cancer Research, University of Lausanne, chemin des Boveresses 155, CH-1066, Epalinges, Switzerland
| | - Michel Obeid
- Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
- Vaccination and Immunotherapy Center, Lausanne University Hospital CHUV, rue du Bugnon 17, CH-1011, Lausanne, Switzerland.
- Medical school Pitié-Salpêtrière, Sorbonne University, 91 Boulevard de l'Hôpital, F-75013, Paris, France.
| |
Collapse
|
19
|
Liapi A, Horisberger A, François S, Ribi C. [Sjögren's syndrome: when to suspect and how to confirm?]. Rev Med Suisse 2016; 12:698-702. [PMID: 27197325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Sjögren's syndrome (SS) is an autoimmune disease leading to mucosal dryness. It may also involve joints, nerves, kidneys and lungs. Patients with SS are also at increased risk for lymphoma. Diagnosis of SS relies on clinical, biological, histological and radiological criteria, after exclusion of other causes. Initial work-up may be performed in general practice, by serology (antinuclear and anti-SSA/SSB antibodies, rheumatoid factor) and by measuring lacrimal and salivary flow. Antibodies may be within normal range in up to one third of patients and when present are not specific for SS. Histological proof of lymphocytic sialadenitis is precious but invasive. Major salivary glands sonography may help select candidates for labial biopsy. This article elaborates the steps to be taken in case of suspected SS, in order to facilitate early diagnosis.
Collapse
|